Korea Osimertinib Real world Evidence study to Assess safety and efficacy – PLUS - KOREA-PLUS

Study identifier:D5161R00005

ClinicalTrials.gov identifier:NCT03918304

EudraCT identifier:N/A

CTIS identifier:N/A

Recruiting

Official Title

Open Label, Multicenter, Real World Treatment Study of Single Agent Tagrisso; KOREA PLUS study (Korea Osimertinib Real world Evidence study to Assess safety and efficacy – PLUS).

Medical condition

Carcinoma, Non-Small-Cell Lung

Phase

N/A

Healthy volunteers

No

Study drug

-

Sex

All

Estimated Enrollment

852

Study type

Observational

Age

n/a - n/a

Date

Study Start Date: 11 Jun 2019
Estimated Primary Completion Date: 30 Jun 2024
Estimated Study Completion Date: 30 Jun 2024

Study design

Allocation: N/A
Endpoint Classification: -
Intervention Model: Single Group Assignment
Masking: -
Primary Purpose: -

Verification:

Verified 01 Feb 2024 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria